Viome Life Sciences

Viome, Inc.Founded in 2016 and headquartered in Bellevue, US, Viome Life Sciences, Inc. focuses on delivering microbiome health testing solutions.Viome Life Sciences specializes in at-home microbiome health testing, primarily offering three core products: the Full Body Intelligence™ Test, the Gut Intelligence™ Test, and the Oral Health Intelligence™ Test. These tests utilize RNA sequencing technology to analyze the activities of the microbiome and cellular functions, providing users with personalized health insights and recommendations tailored to their unique biological profiles. The end use cases for these products include addressing digestive issues, optimizing energy levels, improving mood and cognitive function, and enhancing overall health and wellness. Viome primarily serves individual consumers seeking personalized health solutions and has a growing customer base that includes health-conscious individuals, athletes, health coaches, and those suffering from chronic health issues.Viome operates on a direct-to-consumer model, generating revenue through the sale of its microbiome health tests and personalized product subscriptions. Customers can purchase individual tests or opt for health solution bundles that include monthly deliveries of custom-formulated supplements and biotic formulas designed based on test results. The pricing structure typically involves one-time payments for individual tests, while subscription services for personalized products create a recurring revenue stream. Viome's flagship offerings, such as the Full Body Intelligence™ Test, are part of these transactions, enabling customers to receive actionable insights into their health.In August 2024, Viome, Inc. The company is planning to expand its product lineup and enter new geographic markets to further its reach. Specific expansion plans include targeting additional international markets by the end of 2025.

1. Series D

   Aug 19, 2024

   Amount

   $25M

   Investors

   Locked

2. Series C

   Aug 18, 2023

   Amount

   $87M

   Investors

   Locked

3. Series C

   Sep 27, 2022

   Amount

   $67M

   Investors

   Locked

4. Series B

   Apr 17, 2019

   Amount

   $25M

   Investors

   Locked

5. Series B

   Aug 2, 2018

   Amount

   $9.1M

   Investors

   Locked

6. Series B

   Jun 21, 2018

   Amount

   $5.5M

   Investors

   Locked

7. Series A

   Jul 28, 2017

   Amount

   $15M

   Investors

   Locked